Strategic ownership BIOCORP is a French medical equipment manufacturer and a 100% Novo Nordisk company since October 2023, indicating strong backing and potential long-term procurement opportunities for devices and components related to diabetes management and connected patient devices.

Diabetes focus Their flagship Mallya device turns insulin pens into smart devices, signaling ongoing demand for digital health enhancements in diabetes care and opportunities to upsell additional connected solutions or insulin pen accessories and data services.

Regional footprint R&D and operations are centered in Clermont-Ferrand with production in Issoire and a mid-sized workforce, suggesting a preference for local European supply chain partners and potential for local collaboration, co-development, and rapid prototyping.

Growth with agility The company emphasizes startup spirit, agility, and well-being at work, which can be leveraged to position rapid integration of new connected device projects, streamlined QA/regulatory support, and flexible manufacturing partnerships.

Financial foothold Revenue in the $25M–$50M range with Novo Nordisk backing signals scalable demand and potential for multi-year procurement collaborations, device line extensions, and strategic partnerships to expand into adjacent connected medical devices.